Countdown to CDW (CDW) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts anticipate CDW's Q2 earnings at $2.49 per share, a 0.4% year-over-year decrease, on revenues of $5.51 billion, a 1.6% increase, with the consensus EPS estimate holding steady for 30 days. Deeper insights into segment performance reveal expected strength in Public-Healthcare (+11%) and Corporate sales (+3.1%), contrasting with projected declines in Public-Government (-3.8%) and Public-Education (-5%). Despite CDW shares falling 7.3% over the last month, the company carries a Zacks Rank #2 (Buy), indicating potential near-term market outperformance.

Analysis

Ahead of its Q2 earnings release, CDW Corporation is facing a mixed but stable set of Wall Street expectations. The consensus forecast points to nearly flat earnings at $2.49 per share, a 0.4% year-over-year decline, on revenues of $5.51 billion, representing modest 1.6% growth. The stability of the EPS estimate over the past 30 days suggests analysts see little reason to alter their outlook. A deeper look at segment forecasts reveals a significant divergence in performance. Strength is anticipated in the Public-Healthcare segment, with projected growth of 11%, and in the Corporate segment, which is expected to grow by 3.1%. However, this is largely offset by expected declines in Public-Education (-5%) and Public-Government (-3.8%), leading to an overall forecast of a slight 0.4% contraction in the 'Net sales-Public' division. Similarly, hardware sales are projected to be flat-to-down at -0.6%, with modest growth in Notebooks/Mobile Devices (+1.2%) and Desktops (+3.7%) insufficient to counter weakness elsewhere. Despite this tepid fundamental outlook, which has coincided with the stock's 7.3% underperformance relative to the S&P 500 over the last month, the company holds a Zacks Rank #2 (Buy), indicating a potential for near-term market outperformance.

Key Decisions for Investors

• Investors should look past the flat headline figures and focus on segment-level results, as any significant beat will likely need to be driven by the Healthcare (+11% estimate) and Corporate (+3.1% estimate) divisions offsetting public sector weakness.
• Given the stock's recent 7.3% underperformance against the market, negative sentiment may be priced in, potentially offering a favorable entry point for those confident that CDW can meet or exceed these modest, stable expectations.
• Monitor management commentary closely for any signs of an accelerating hardware refresh cycle, as growth in the Desktop category (+3.7% estimate) could be an early, albeit small, indicator of a broader trend that is not yet reflected in consensus forecasts.